DrugId:  1
1. Name:  GW 597599
2. Groups:  Investigational
3. Description:  GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).
DrugId:  2
1. Name:  CX157
2. Groups:  Investigational
3. Description:  CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
4. Indication:  Anxiety Disorders I,Depression I
DrugId:  3
1. Name:  ADX10059
2. Groups:  Investigational
3. Description:  ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
4. Indication:  Investigated for use/treatment in anxiety disorders, gastroesophageal reflux disease (GERD), and migraine and cluster headaches.
DrugId:  4
1. Name:  Filanesib
2. Groups:  Investigational
3. Description:  Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
4. Indication:  Investigated for use/treatment in cancer/tumors (unspecified).
DrugId:  5
1. Name:  MN-305
2. Groups:  Investigational
3. Description:  MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
4. Indication:  Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.
DrugId:  6
1. Name:  MRK-409
2. Groups:  Experimental
3. Description:  MRK-409 is a GABA-A receptor agonist [1].
4. Indication:  Not Available
DrugId:  7
1. Name:  Imagabalin
2. Groups:  Investigational
3. Description:  Imagabalin has been investigated in Generalized Anxiety Disorder.
4. Indication:  Not Available
DrugId:  8
1. Name:  R673
2. Groups:  Investigational
3. Description:  R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning of limbic system with respect to anxiety and depression.
4. Indication:  Investigated for use/treatment in depression and anxiety.
DrugId:  9
1. Name:  Lumateperone
2. Groups:  Investigational
3. Description:  Lumateperone (ITI-722/ITI-007) is a novel, first-in-class dual 5HT2A receptor antagonist/dopamine phosphoprotein modulator (DPPM) for schizophrenia. It is an orally available compound which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As of May 2015, Lumateperone is in phase III clinical trials for schizophrenia.
4. Indication:  Investigated for use/treatment in schizophrenia and schizoaffective disorders.
DrugId:  10
1. Name:  Cloxazolam
2. Groups:  Approved, Investigational
3. Description:  Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.
4. Indication:  Used primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to surgery. 
DrugId:  11
1. Name:  Cyamemazine
2. Groups:  Approved
3. Description:  Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
4. Indication:  Not Available
DrugId:  12
1. Name:  MK-0777
2. Groups:  Investigational
3. Description:  MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
4. Indication:  Not Available
DrugId:  13
1. Name:  ND7001
2. Groups:  Investigational
3. Description:  ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.
4. Indication:  Investigated for use/treatment in anxiety disorders and depression.
DrugId:  14
1. Name:  Naluzotan
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in anxiety disorders and depression.
DrugId:  15
1. Name:  Deramciclane
2. Groups:  Investigational
3. Description:  Deramciclane (EGIS-3886) is a non-benzodiazepine-type anxiolytic drug to treat various types of anxiety disorders. Deramciclane is a unique alternative to current anxiolytics on the market because it has a novel chemical structure and target. It acts as an antagonist at the 5-HT2A receptor, as an inverse agonist at the 5-HT2C receptor, and as a GABA reuptake inhibitor.
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  16
1. Name:  Cenobamate
2. Groups:  Investigational
3. Description:  YKP-3089 is a novel small molecule that is currently under development as an anxiolytic therapeutic agent. The exact mechanism(s) by which YKP3089 exerts its effects remain under active investigation.
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  17
1. Name:  Prazepam
2. Groups:  Approved, Illicit
3. Description:  Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
4. Indication:  For the treatment of anxiety disorders.
DrugId:  18
1. Name:  Pagoclone
2. Groups:  Investigational
3. Description:  Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.
4. Indication:  For the potential treatment of panic and anxiety disorders.
DrugId:  19
1. Name:  Benzoctamine
2. Groups:  Approved
3. Description:  Benzoctamine is a drug that possesses sedative and anxiolytic properties. It is different from most sedative drugs because in most clinical trials it does not produce respiratory depression, but actually stimulates the respiratory system. Benzoctamine has been found to have the same efficacy as chlordiazepoxide when treating anxiety neurosis.
4. Indication:  Not Available
DrugId:  20
1. Name:  Cinolazepam
2. Groups:  Approved
3. Description:  Cinolazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada.
4. Indication:  For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
DrugId:  21
1. Name:  Etifoxine
2. Groups:  Investigational, Withdrawn
3. Description:  Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing. It has similar effects to benzodiazepine drugs, but is structurally distinct and does not bind to the benzodiazepine receptor. It is more effective than lorazepam as an anxiolytic, and has fewer side effects. Etifoxine has been associated with acute liver injury.
4. Indication:  Not Available
DrugId:  22
1. Name:  Captodiame
2. Groups:  Approved, Investigational
3. Description:  Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.
4. Indication:  Captodiame is indicated for the treatment of anxiety. 
DrugId:  23
1. Name:  Meprobamate
2. Groups:  Approved, Illicit
3. Description:  A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
4. Indication:  For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
DrugId:  24
1. Name:  Prothipendyl
2. Groups:  Investigational
3. Description:  Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
4. Indication:  Not Available
DrugId:  25
1. Name:  Clotiazepam
2. Groups:  Approved, Illicit
3. Description:  Clotiazepam is a benzodiazepine derivative, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.
4. Indication:  For the treatment of anxiety disorders.
